PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US69404D1081
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 160.01 m USD |
| Gross profit | 45.78 m USD |
| Operating income | -553.86 m USD |
| EBIT | -539.10 m USD |
| Net income | -546.38 m USD |
| Diluted EPS – continuing operations | -1.82 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
More stocks
- Yext, Inc. (YEXT)
- Shenzhen LeoKing Environmental Group Co. Ltd. A (301305.SZ)
- Criteo S.A. (CRTO)
- YIFILASER ORD A (SHH) EQSW Exp: (688646.SS)
- DINE S.A.B. de C.V (DINEB.MX)
- Schroder Asian Total Return Investment Company PLC (ATR.L)
- Liberty Gold Corp (LGD.TO)
- Dakota Gold Corp. (DC)
- Copper Property CTL Pass Through Trust (CPPTL)
- Jiangsu Zhenjiang New Energy Equipment Co Ltd Class A (603507.SS)
- Hengerda New Materials (Fujian) Co. Ltd. (300946.SZ)
- Carlyle Secured Lending, Inc. (CGBD)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.